[Aminoglycoside levels in bronchial secretions]

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pharmacology

Background:

• Aminoglycosides show limited clinical efficacy for gram-negative bacillary pneumonia.
• Poor drug penetration and local inactivation lead to inadequate levels in bronchial secretions.
• Low therapeutic-to-toxic ratio contributes to the limited efficacy of systemic aminoglycosides.

Purpose of the Study:

• To evaluate the efficacy and safety of endotracheal aminoglycoside administration for gram-negative bacillary pneumonia.
• To determine if direct airway delivery can overcome pharmacokinetic limitations of systemic aminoglycosides.
• To assess the impact of endotracheal injection on drug concentrations within the bronchial lumen and clinical outcomes.

Main Methods:

• Aminoglycosides were administered via endotracheal injection in patients with gram-negative bacillary pneumonia.
• Bactericidal activity in bronchial secretions was measured.
• Clinical efficacy and systemic toxicity were monitored.
• Drug levels in bronchial secretions were compared to minimal inhibitory concentrations.

Main Results:

• Endotracheal injection of aminoglycosides achieved high bactericidal activity within the bronchial lumen.
• Clinical efficacy was increased compared to standard systemic administration.
• Systemic toxicity was not increased by the endotracheal route.
• Achieved drug concentrations in bronchial secretions were adequate against gram-negative strains.

Conclusions:

• Endotracheal aminoglycoside administration can enhance efficacy in treating gram-negative bacillary pneumonia by achieving bactericidal concentrations locally.
• This method offers a potential alternative to systemic therapy, particularly when conventional treatment fails.
• Due to potential risks associated with topical antibiotics, endotracheal treatment should be reserved for carefully selected patients.